3 Results for "

CD70-positive tumors

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "CD70-positive tumors" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-178271
CAS No.: 147597-66-8
Target:  

Drug Intermediate

Research Areas:  

Cancer

P-SCN-Bn-NOTA is a metal chelator and molecular imaging probe precursor that allows radiolabeling with Ga-68. P-SCN-Bn-NOTA can be conjugated to CD70-specific molecules B3, B6, ABDB3 and ABDB6 to form NOTA-labeled derivatives. P-SCN-Bn-NOTA is applicable for preclinical PET/CT imaging of CD70-expressing tumors in NCG mouse PDX models. P-SCN-Bn-NOTA can be used in studies related to CD70-positive tumors .
loading...
    loading...
Cat. No.: HY-P991930

Research Areas:  

Cancer

ARX305 Antibody is a high-affinity, humanized anti-CD70 antibody. ARX305 Antibody forms an antibody-drug conjugate (ADC) (ARX305) with the potent microtubule inhibitor PEG4-aminooxy-MMAF (AS269) (HY-128968). As a targeting component, ARX305 Antibody mediates the binding and internalization of ARX305 to CD70-positive tumor cells, whereas the unconjugated ARX305 Antibody exhibits only weak anti-tumor activity in various xenograft and disseminated tumor models. ARX305 Antibody can be used in the research of a variety of solid tumors and hematological malignancies .
loading...
    loading...